Skip to content

Study · Randomized controlled trial · n = 85 · 2017

2 results

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival.

Rinke A, Wittenberg M, Schade-Brittinger C, Aminossadati B, Ronicke E, Gress TM, Müller HH, Arnold R

Neuroendocrinology6 Jan 2016Cited by 266 (Europe PMC)

PMID26731483 (opens in a new tab)DOI10.1159/000443612 (opens in a new tab)PepBankPUB-26731483
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with metastatic neuroendocrine midgut tumors, median overall survival was only slightly different between octreotide LAR (84.7 months) and placebo (83.7 months) (HR 0.83; p = 0.51).

    In plain wordsIn patients with metastatic midgut tumors, survival was slightly longer with initial octreotide than placebo, without a significant difference.

    Peptide
    Octreotide
    Outcome
    IncreaseOverall survival
    Study

    n = 85

    Comparator
    placebo; 38 of 43 placebo patients (88.4%) received octreotide LAR upon progression
    Outcome group
    Mortality · Cancer
    Studied dose
    30 mg monthly · until tumor progression or deathAs given in this study (human).

    Measurements

    Median overall survival
    84.7 months
    octreotide
    Median overall survival
    83.7 months
    placebo
    HR
    0.83
    reported comparison
    95% CI
    0.47 to 1.46
    reported comparison

    Source sentences

    Summary
    The median overall survival (84.7 and 83.7 months) was only slightly different in patients assigned to octreotide and placebo [HR = 0.83 (95% CI: 0.47-1.46); p = 0.51].
    3 context sentences
    Summary · context
    Between 2001 and 2008, 85 treatment-naïve patients were randomly assigned to monthly octreotide LAR 30 mg or placebo until tumor progression or death.
    Summary · context
    Upon disease progression, 38 out of 43 placebo patients (88.4%) received octreotide LAR.
    Summary · context
    For survival, patients were followed until May 2014.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with a low hepatic tumor load, there was a trend toward improved overall survival with octreotide versus placebo (median not reached versus 87.2 months; HR 0.59; p = 0.142).

    In plain wordsIn patients with low hepatic tumor load, survival tended to be longer with octreotide than placebo, without a significant difference.

    Peptide
    Octreotide
    Outcome
    IncreaseOverall survival with low hepatic tumor load
    Study

    n = 64

    Comparator
    placebo; 38 of 43 placebo patients in the whole trial (88.4%) received octreotide LAR upon progression
    Outcome group
    Mortality · Cancer
    Studied dose
    30 mg monthly · until tumor progression or deathAs given in this study (human).

    Measurements

    Median overall survival
    87.2 months
    placebo
    HR
    0.59
    reported comparison
    95% CI
    0.29 to 1.2
    reported comparison

    Source sentences

    Summary
    There was a trend towards improved overall survival in patients with a low hepatic tumor load receiving octreotide compared to placebo ['median not reached' and 87.2 months; HR = 0.59 (95% CI: 0.29-1.2); p = 0.142].
    3 context sentences
    Summary · context
    Between 2001 and 2008, 85 treatment-naïve patients were randomly assigned to monthly octreotide LAR 30 mg or placebo until tumor progression or death.
    Summary · context
    Upon disease progression, 38 out of 43 placebo patients (88.4%) received octreotide LAR.
    Summary · context
    For survival, patients were followed until May 2014.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.